Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EVAXNASDAQ:PKBONASDAQ:PTIXNASDAQ:VCNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVAXEvaxion Biotech A/S$2.65-4.3%$1.86$1.20▼$17.75$3.72M0.1614,500 shs36,978 shsPKBOPeak Bio$0.02$0.05$0.00▼$0.26$520K1.758,940 shs66,140 shsPTIXProtagenic Therapeutics$3.41+2.7%$3.83$2.35▼$15.82$2.01M0.36562,336 shs25,937 shsVCNXVaccinex$0.71-13.4%$0.81$0.25▼$8.90$1.85M1.156,118 shs3,472 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVAXEvaxion Biotech A/S0.00%-11.50%+59.07%+48.13%-82.13%PKBOPeak Bio0.00%0.00%0.00%0.00%+150.00%PTIXProtagenic Therapeutics0.00%-8.29%+9.57%-15.31%-76.98%VCNXVaccinex0.00%-4.09%-21.15%+24.24%-88.04%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEVAXEvaxion Biotech A/S1.9802 of 5 stars3.52.00.00.02.51.70.0PKBOPeak BioN/AN/AN/AN/AN/AN/AN/AN/APTIXProtagenic Therapeutics1.3206 of 5 stars0.04.00.00.04.11.70.0VCNXVaccinexN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEVAXEvaxion Biotech A/S 3.00Buy$10.00277.36% UpsidePKBOPeak Bio 0.00N/AN/AN/APTIXProtagenic Therapeutics 0.00N/AN/AN/AVCNXVaccinex 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PKBO, VCNX, PTIX, and EVAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/2/2025EVAXEvaxion Biotech A/SHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEVAXEvaxion Biotech A/S$3.29M1.13N/AN/A($5.83) per share-0.45PKBOPeak Bio$370K1.41N/AN/A($0.90) per share-0.03PTIXProtagenic TherapeuticsN/AN/AN/AN/A$0.83 per shareN/AVCNXVaccinex$388K4.76N/AN/A($2.59) per share-0.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEVAXEvaxion Biotech A/S-$22.12M-$1.16N/AN/AN/A-347.83%N/A-79.40%8/12/2025 (Estimated)PKBOPeak Bio-$12.83M-$0.16N/A∞N/AN/AN/A-179.31%N/APTIXProtagenic Therapeutics-$5M-$13.11N/A∞N/AN/A-308.97%-228.73%8/12/2025 (Estimated)VCNXVaccinex-$20.25M-$48.27N/A∞N/AN/AN/A-383.58%8/12/2025 (Estimated)Latest PKBO, VCNX, PTIX, and EVAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/27/2025Q1 2025EVAXEvaxion Biotech A/S-$0.65-$0.29+$0.36-$0.29$0.06 millionN/A5/13/2025Q1 2025PTIXProtagenic TherapeuticsN/A-$2.75N/A-$2.75N/AN/A4/1/2025Q4 2024EVAXEvaxion Biotech A/S-$0.26-$0.07+$0.19-$0.07$1.66 million$0.12 million3/31/2025Q4 2024PTIXProtagenic TherapeuticsN/A-$3.36N/A-$0.24N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEVAXEvaxion Biotech A/SN/AN/AN/AN/AN/APKBOPeak BioN/AN/AN/AN/AN/APTIXProtagenic TherapeuticsN/AN/AN/AN/AN/AVCNXVaccinexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEVAXEvaxion Biotech A/S7.991.002.80PKBOPeak BioN/A0.070.06PTIXProtagenic TherapeuticsN/A1.801.80VCNXVaccinexN/A0.770.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEVAXEvaxion Biotech A/S11.04%PKBOPeak BioN/APTIXProtagenic Therapeutics7.97%VCNXVaccinex50.11%Insider OwnershipCompanyInsider OwnershipEVAXEvaxion Biotech A/S41.64%PKBOPeak Bio19.90%PTIXProtagenic Therapeutics35.00%VCNXVaccinex51.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEVAXEvaxion Biotech A/S601.40 million685,000No DataPKBOPeak Bio323.13 million18.52 millionNot OptionablePTIXProtagenic Therapeutics2589,0004.71 millionNot OptionableVCNXVaccinex402.60 million1.26 millionNo DataPKBO, VCNX, PTIX, and EVAX HeadlinesRecent News About These CompaniesVaccinex presents promising cancer treatment data at ASCOMay 29, 2025 | uk.investing.comVaccinex, Inc. to Present New Data on Pepinemab's Role in Enhancing Immune Responses in Head and Neck Cancer at ASCO 2025May 29, 2025 | nasdaq.comVaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual MeetingMay 27, 2025 | globenewswire.comAbTherx, Inc: AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug TargetsMay 13, 2025 | finanznachrichten.deAbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug TargetsMay 13, 2025 | finance.yahoo.comVaccinex to report new clinical data on pepinemab in enhancing immunotherapyApril 22, 2025 | markets.businessinsider.comVaccinex, Inc. Announces Promising Data on Pepinemab as Neoadjuvant Immunotherapy in Metastatic Melanoma and Head and Neck Cancer at AACR 2025April 21, 2025 | quiverquant.comVaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)April 21, 2025 | globenewswire.comVaccinex director resigns, no disagreement citedMarch 21, 2025 | investing.comVaccinex plans Nasdaq exit as Alzheimer market pressure growsMarch 11, 2025 | finance.yahoo.comVaccinex, Inc.: Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock MarketMarch 8, 2025 | finanznachrichten.deVaccinex to delist common stock from NasdaqMarch 7, 2025 | markets.businessinsider.comVaccinex Plans to Delist its Common Stock from The Nasdaq Stock MarketMarch 7, 2025 | globenewswire.comPepinemab by Vaccinex for Alzheimer’s Disease: Likelihood of ApprovalDecember 30, 2024 | pharmaceutical-technology.comVaccinex receives delisting notification from NasdaqDecember 17, 2024 | markets.businessinsider.comVaccinex Announces Receipt of Delisting Notification from NasdaqDecember 17, 2024 | markets.businessinsider.comVaccinex Shares Tumble 63% On Nasdaq DelistingDecember 17, 2024 | marketwatch.comVaccinex Faces Nasdaq Delisting Amid Financial Struggles; Shares Drop 62%December 17, 2024 | finance.yahoo.comVaccinex Faces Nasdaq Delisting: What's Going On With The Stock?December 17, 2024 | benzinga.comVaccinex, Inc. Faces Delisting from Nasdaq Due to Failure to Meet Continued Listing StandardsDecember 17, 2024 | quiverquant.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePKBO, VCNX, PTIX, and EVAX Company DescriptionsEvaxion Biotech A/S NASDAQ:EVAX$2.65 -0.12 (-4.33%) As of 12:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.Peak Bio NASDAQ:PKBOPeak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. The company's lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is based in Pleasanton, California.Protagenic Therapeutics NASDAQ:PTIX$3.41 +0.09 (+2.71%) As of 12:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.Vaccinex NASDAQ:VCNX$0.71 -0.11 (-13.41%) As of 11:21 AM EasternVaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 2 Reasons Adobe Stock Is Ready to Rally This Year AMD Accelerates Stack Development: Share Price to Follow Alphabet Enters a Bull Market: Is It Time to Buy? Micron Joins Latest $200 Billion United States Investment Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Tariff Talks Advance, What Taiwan Semiconductor Can Deliver Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
